VOXZOGO added 2.33 cm a year in Phase 3. Can BioMarin turn that growth signal into a new FDA indication?
BioMarin’s VOXZOGO met its Phase 3 hypochondroplasia endpoint with a 2.33 cm/year growth velocity benefit as an FDA filing moves forward.
Pharma & Biotech
Pharma & Biotech
BioMarin closes $275m Alesta deal to add first potential oral hypophosphatasia therapy
BioMarin Pharmaceutical has completed its acquisition of Alesta Therapeutics, adding Phase 1/2a candidate ALE1, an oral small molecule designed to target the metabolic abnormality driving hypophosphatasia.